The impact of modern preoperative high-dose-rate brachytherapy in early-stage cervical cancer

被引:10
|
作者
Cagetti, Leonel Varela [1 ]
Gonzague-Casabianca, Laurence [1 ]
Zemmour, Christophe [2 ]
Lambaudie, Eric [3 ]
Houvenaeghel, Gilles [3 ,4 ,7 ]
Provansal, Magalie [5 ]
Sabatier, Renaud [5 ,8 ]
Sabiani, Laura [6 ]
Blache, Guillaume [6 ]
Jauffret, Camille [6 ]
Ferre, Marjorie [7 ]
Mailleux, Hugues [7 ]
Paciencia, Maria [9 ]
Tallet, Agnes [1 ]
机构
[1] Inst Paoli Calmettes, Dept Radiat Oncol, 232 Blvd St Marguerite, F-13009 Marseille, France
[2] Aix Marseille Univ, Inst Paoli Calmettes, Dept Clin Res & Invest, Biostat & Methodol Unit,INSERM,IRD,SESSTIM, Marseille, France
[3] Aix Marseille Univ, Inst Paoli Calmettes, Dept Surg Oncol, CNRS,INSERM,CRCM, F-13000 Marseille, France
[4] Aix Marseille Univ, INSERM, CNRS, Inst Paoli Calmettes,CRCM, Marseille, France
[5] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France
[6] Inst Paoli Calmettes, Dept Oncol Surg 2, Marseille, France
[7] Inst Paoli Calmettes, Dept Med Phys, Marseille, France
[8] Inst Paoli Calmettes, Dept Mol Oncol, CNRS, INSERM,UMR1068,UMR725, Marseille, France
[9] Inst Paoli Calmettes, Dept Biopathol, Marseille, France
关键词
Early-stage cervical cancer; Image-guided adaptive brachytherapy; Preoperative brachytherapy; Minimally invasive surgery; Hysterectomy; PATHOLOGICAL COMPLETE REMISSION; LYMPH-NODE BIOPSY; UTERINE CERVIX; RADICAL HYSTERECTOMY; RANDOMIZED-TRIAL; PROGNOSTIC VALUE; EARLY CARCINOMA; FOLLOW-UP; IB; RADIOTHERAPY;
D O I
10.1016/j.ygyno.2021.01.034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. To analyze the clinical outcomes and the safety of preoperative high-dose-rate (HDR) image-guided adaptive brachytherapy (IGABT) followed by minimally invasive surgery (MIS) in the multidisciplinary manage-ment of early-stage cervical cancer. Methods and materials. Medical records of all consecutive patients with early-stage cervical cancer treated at our institution between 2012 and 2018 with preoperative IGABT in a multidisciplinary approach were reviewed. Treatment schedule was pelvic node dissection, preoperative IGABT followed 6-8 weeklater by MIS hysterectomy. Results. Seventy patients with cervical cancer FIGO stages (IB1 18.6%, IB2 75.7% and IIA1 5.7%) were treated by preoperative HDR brachytherapy. With a median follow-up of 37.4 months [95% confidence interval, 32.1-39.7 months] isolated vaginal vault recurrence was not observed, 3 pelvic relapses were reported (4.3%). None of patients received postoperative radiotherapy (EBRT) or radiochemotherapy. The estimated 3-year local and pelvis relapse free survival for the entire population were respectively 98% [95% confidence interval, 89%-100%] and 90% [80%-96%]. The estimated 3-year disease-free survival (DFS) for the entire population was 88% [77-94%]. The 3-year overall survival (OS) rate was 97% [88%-99%]. Microscopic vaginal resection margin (R1) was observed in one patient ([1].4%). Lymph-vascular space invasion (LVSI) was found found in 6 (8.6%) patients. Forty-eight late complications in 36 patients (51.4%) were observed. Five (7.1%) grade 3 vaginal wound dehiscence toxicities were observed. Urinary and gastrointestinal toxicities were grade 1-2. No grade 4-5 complications were observed. Conclusions. Preoperative image-guided adaptive brachytherapy followed by minimally invasive surgery allows high local control, reduces positive surgical margins and rates of lymph-vascular space invasion avoiding adjuvants treatments. Surgical approaches must be discussed with patients including preoperative brachytherapy as a down-staging treatment. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 50 条
  • [1] Pre-operative high-dose-rate brachytherapy in early-stage cervical cancer: long-term single-center results
    Kellas-Sleczka, Sylwia
    Wojcieszek, Piotr
    Szlag, Marta
    Stankiewicz, Magdalena
    Cholewka, Agnieszka
    Sleczka, Maciej
    Badora-Rybicka, Agnieszka
    Lelek, Piotr
    Pruefer, Agnieszka
    Krzysztofiak, Tomasz
    Kolosza, Zofia
    Fijalkowski, Marek
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2022, 14 (01) : 43 - 51
  • [2] Interstitial preoperative high-dose-rate brachytherapy for early stage cervical cancer: Dose-volume histogram parameters, pathologic response and early clinical outcome
    Hannoun-Levi, Jean-Michel
    Chand-Fouche, Marie-Eve
    Gautier, Mathieu
    Dejean, Catherine
    Marcy, Myriam
    Fouche, Yves
    BRACHYTHERAPY, 2013, 12 (02) : 148 - 155
  • [3] Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group
    Ka, Kanta
    Cordoba, Abel
    Cagetti, Leonel Varela
    Schiappa, Renaud
    Kissel, Manon
    Escande, Alexandre
    Casabianca, Laurence Gonzague
    Buchalet, Chloe
    Gouy, Sebastien
    Morice, Philippe
    Narducci, Fabrice
    Martinez, Carlos
    Jauffret, Camille
    Lambaudie, Eric
    Delpech, Yann
    Laas, Enora
    Gaillard, Thomas
    Hannoun-Levi, Jean-Michel
    Espenel, Sophie
    Chargari, Cyrus
    GYNECOLOGIC ONCOLOGY, 2024, 188 : 90 - 96
  • [4] DVH parameters and outcome for patients with early-stage cervical cancer treated with preoperative MRI-based low dose rate brachytherapy followed by surgery
    Haie-Meder, Christine
    Chargari, Cyrus
    Rey, Annie
    Dumas, Isabelle
    Morice, Philippe
    Magne, Nicolas
    RADIOTHERAPY AND ONCOLOGY, 2009, 93 (02) : 316 - 321
  • [5] Preoperative high-dose-rate brachytherapy for high-risk early-stage cervical cancer: Long-term clinical outcome analysis
    Gauci, Pierre-Alexis
    Kee, Daniel Lam Cham
    Thamphya, Brice
    Schiappa, Renaud
    Delotte, Jerome
    Chand-Fouche, Marie-Eve
    Hannoun-Levi, Jean-Michel
    BRACHYTHERAPY, 2022, 21 (03) : 273 - 282
  • [6] Predicting factors for locoregional failure of high-dose-rate brachytherapy for early-stage oral cancer
    Petera, Jiri
    Sirak, Igor
    Tucek, Lubos
    Hodek, Miroslav
    Paluska, Petr
    Kasaova, Linda
    Paulikova, Simona
    Vosmik, Milan
    Dolezalova, Helena
    Cvanova, Michaela
    Halamka, Magdalena
    Laco, Jan
    PERSONALIZED MEDICINE, 2012, 9 (08) : 879 - 887
  • [7] Clinical Impact of Escalating Relative High-dose-rate Intracavitary Brachytherapy Dose in Stage IIB Cervical Cancer
    Cho, Oyeon
    Noh, O. Kyu
    Oh, Young-Taek
    Chang, Suk-Joon
    Chun, Mison
    ANTICANCER RESEARCH, 2017, 37 (01) : 327 - 334
  • [8] High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy
    Kozai, Yuka
    Itoh, Yoshiyuki
    Kawamura, Mariko
    Nakahara, Rie
    Ito, Junji
    Okada, Tohru
    Kikkawa, Fumitaka
    Ikeda, Mitsuru
    Naganawa, Shinji
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2019, 81 (03): : 351 - 358
  • [9] Pathologic Complete Remission after Preoperative High-Dose-Rate Brachytherapy in Patients with Operable Cervical Cancer: Preliminary Results of a Prospective Randomized Multicenter Study
    Vizkeleti, Julia
    Vereczkey, Ildiko
    Froehlich, Georgina
    Varga, Szilvia
    Horvath, Katalin
    Pulay, Tamas
    Pete, Imre
    Nemeskeri, Csaba
    Mayer, Arpad
    Sipos, Norbert
    Kasler, Miklos
    Polgar, Csaba
    PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (02) : 247 - 256
  • [10] Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients
    Folkert, Michael R.
    Cohen, Gil'ad N.
    Wu, Abraham J.
    Gerdes, Hans
    Schattner, Mark A.
    Markowitz, Arnold J.
    Ludwig, Emmy
    Ilson, David H.
    Bains, Manjit S.
    Zelefsky, Michael J.
    Goodman, Karyn A.
    BRACHYTHERAPY, 2013, 12 (05) : 463 - 470